Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer

PURPOSE: Gonadotropin-releasing hormone (GnRH) agonists decrease bone mineral density (BMD) and increase fracture risk in men with prostate cancer. Annual zoledronic acid increases BMD in postmenopausal women, but its efficacy in hypogonadal men is not known. PATIENTS AND METHODS: In a 12-month stud...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Michaelson, M. Dror, Kaufman, Donald S., Lee, Hang, McGovern, Francis J., Kantoff, Philip W., Fallon, Mary Anne, Finkelstein, Joel S., Smith, Matthew R.
Format: Artigo
Langue:Inglês
Publié: 2007
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3047397/
https://ncbi.nlm.nih.gov/pubmed/17369566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2006.07.3361
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires